Distress screening and referral program for adults with newly diagnosed solid tumors
Official title: A Pilot Distress Screening and Referral Program to Detect Comorbid Psychosocial Distress in NYC Safety Net Hospitals Serving Diverse and Underserved Patients Diagnosed With Cancer
Run by Memorial Sloan Kettering Cancer Center · NCT07117461 · Data updated 2026-11-12
This program will try a distress screening and referral process using the NCCN Distress Thermometer to help English- and Spanish-speaking adults newly diagnosed with solid tumors get connected to mental health support.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Locations | 2 sites (New York, New York and 1 other locations) |
| Status | Recruiting |
| Started | July 22, 2025 |
| Main results expected | July 22, 2027 |
| Study ends | July 22, 2027 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT07117461 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) with a new solid tumor diagnosis who are treated or will be treated at Jamaica Hospital Medical Center, prefer English or Spanish for healthcare, and can provide consent.
✕Probably not a fit
Patients not receiving care at the participating sites, those whose preferred language is not English or Spanish, or those unable to provide informed consent (for example due to cognitive impairment) may not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional program implements the NCCN Distress Thermometer to screen adults with newly diagnosed solid tumors for psychological distress and refer those above a threshold to mental health services. Enrollment includes English- and Spanish-preferred patients age 18 and older receiving care at Jamaica Hospital Medical Center, with protocol activities coordinated by Memorial Sloan Kettering Cancer Center and data collection supported by Medisys Health Network. The program records distress scores in the electronic medical record and follows referral uptake and subsequent contact with mental health providers. The aim is to determine whether routine, language-inclusive screening and referral improves identification and connection to psychosocial care across a diverse patient population.
Why it matters
Potential benefit: If successful, the program could increase timely identification of distress and connect more newly diagnosed patients to mental health care.
How similar studies have gone: Use of the NCCN Distress Thermometer and similar screening tools is common and effective at identifying distressed patients, but prior programs have shown mixed results in consistently improving referral uptake and downstream outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * New or recurrent solid tumor cancer diagnosis (per EMR) * Treated or will be treated at Jamaica Hospital Medical Center (per EMR) * Has a NCCN DT score of 0 through 10 (per EMR) * Age ≥ 18 years (per EMR or self-report) * English- or Spanish preferred language for healthcare (per self-report) * Able to provide consent (per completion of consent) Exclusion Criteria: * In the provider or investigative teams' judgement, cognitively not intact to participate in the study (per EMR or investigative team)
Where it's running
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States Recruiting -
Medisys Health Network (Data Collection Only)
Richmond Hill, New York, United States Recruiting
Study contacts
- Principal investigator: Devika Jutagir, PhD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Devika Jutagir, PhD
- Email: jutagird@mskcc.org
- Phone: 646-888-8361
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Urine samples from adults with solid cancers to explore chemistry linked to nearing end of life
This study tests urine chemistry in adults with solid tumors to see if it reflects how close a patient is to death.
-
Tempus Open Link registry for cancer patients using Olivia platform
This registry tests whether Olivia can securely enroll cancer patients and combine their health data from EHRs and patient-reported outcomes to build a large, de-identified dataset.
-
Metronomic low-dose gemcitabine, mitomycin C, and thalidomide for advanced solid tumors
This phase II trial tests a low-dose, continuously given combo of gemcitabine, mitomycin C, and thalidomide in adults with advanced solid tumors to see if it helps control the disease.
-
Imaging with 89Zr-DFO-YS5 to detect cancer
This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.
-
JL19001 Injection Alone or with Standard Therapy in Advanced Solid Tumors or Relapsed/Refractory B-Cell NHL
This phase 1 trial tests JL19001 by itself or with standard treatment to see if it is safe and tolerable in adults with advanced solid tumors or relapsed/refractory B-cell non-Hodgkin lymphoma.
-
Phase 1 dose-escalation and expansion test of IUAb190708 for advanced or recurrent solid tumors
This trial tests IUAb190708, a new cytotoxic anti–PD‑L1 antibody given by IV, to see if it is safe and can kill tumors in adults with advanced or recurrent solid cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.